In the abnormal development and diseases of the central nervous system, JMJD3 was proved to be a biological target in therapeutic strategies nervous system (Raeisossadati et al. 2019); Inhibition of JMJD3 increased the H3K27me3 content of podocytes and attenuated glomerular disease in adriamycin nephrotoxicity, and diabetes (Majumder et al. 2018). This evidence concerns the gene KDM6B and diabetes mellitus.